Liposarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Liposarcoma	No biomarker	Liposarcoma	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Liposarcoma	No biomarker	Liposarcoma	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
No biomarker	Liposarcoma	No biomarker	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
GRM1 overexpression	Liposarcoma	GRM1 overexpression	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
CALB1 underexpression	Liposarcoma	CALB1 underexpression	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
CALB1 deletion	Liposarcoma	CALB1 deletion	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2
PIK3CA mutation	Liposarcoma	PIK3CA mutation	Liposarcoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
RB1 expression	Liposarcoma	RB1 expression	Liposarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
FUS-DDIT3 translocation	Liposarcoma	FUS-DDIT3 translocation	Liposarcoma	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3
MCM4 overexpression	Liposarcoma	MCM4 overexpression	Liposarcoma	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
PIK3CA mutation + TERT promoter mutation	Liposarcoma	PIK3CA mutation + TERT promoter mutation	Liposarcoma	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3
MDM2 amplification + TP53 wild-type	Liposarcoma	MDM2 amplification + TP53 wild-type	Liposarcoma	BI 907828 Sensitive: C3 – Early Trials BI 907828 Sensitive : C3	BI 907828 Sensitive: C3 – Early Trials BI 907828 Sensitive : C3
MDM2 overexpression	Liposarcoma	MDM2 overexpression	Liposarcoma	erdafitinib + RG7388 Sensitive: D – Preclinical erdafitinib + RG7388 Sensitive : D	erdafitinib + RG7388 Sensitive: D – Preclinical erdafitinib + RG7388 Sensitive : D
FGFR1 overexpression	Liposarcoma	FGFR1 overexpression	Liposarcoma	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D
FGFR4 overexpression	Liposarcoma	FGFR4 overexpression	Liposarcoma	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	docetaxel + eribulin mesylate Sensitive: D – Preclinical docetaxel + eribulin mesylate Sensitive : D	docetaxel + eribulin mesylate Sensitive: D – Preclinical docetaxel + eribulin mesylate Sensitive : D
MDM2 amplification + CDK4 amplification	Liposarcoma	MDM2 amplification + CDK4 amplification	Liposarcoma	romidepsin Sensitive: D – Preclinical romidepsin Sensitive : D	romidepsin Sensitive: D – Preclinical romidepsin Sensitive : D

Liposarcoma

Associations(25)

Associations
(25)